Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma

The aim of the trial is to establish an individualized first-line treatment incorporating checkpoint inhibition for early-stage unfavorable cHL, which is effective and well tolerated.

Trial Details

NCT ID
NCT04837859
Phase
PHASE2
Sponsor
University of Cologne
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Tislelizumab
Locations (sample)
  • Cologne, Germany|50.93333,6.95

Key Eligibility Criteria

  • Age 18-60 for the main trial cohort
  • Age ≥ 61 years and eligible for AVD as determined by CIRS-G score and investigator for the exploratory cohort
  • First diagnosis of treatment-naïve cHL
  • Early-stage unfavorable disease (i.e. stage IA, IB and IIA with risk factors a-d, stage IIB with risk factors c-d):

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →